Beyond Cash Flows: A Multi-Agent AI Framework for Valuing Clinical-Stage, Cross-Border Biotechnology

A new class of software systems is transforming investment analysis. Large language model agents assembled into collaborative team structures including analysts, researchers, and risk managers are increasingly deployed across financial markets. Yet current multi-agent frameworks share a critical limitation: they rely on the foundational assumption that companies can be valued through traditional cash flows. This paradigm fails in clinical-stage biotechnology, where enterprise value depends entirely on binary scientific and regulatory milestones. To bridge this gap, this paper introduces a specialized multi-agent framework. Its valuation layer translates qualitative scientific judgment into defensible valuations for pre-revenue assets; its cross-market coordination layer reconciles pricing across international venues simultaneously; and its conflict-fusion mechanism systematically arbitrates between bullish scientific conviction and cautious regulatory constraints in a domain-specific manner. Crucially, the architecture is not a speculative design: it encodes a method the author first executed by hand as sole portfolio manager of China's first dedicated cross-border biotechnology fund, a human practice that returned 127.17% against a 50.67% benchmark within sixteen months. That record is evidence for the underlying method rather than for any AI system; no implementation is evaluated here. This paper presents the framework at the architectural level, establishing foundational design principles for extending agentic investment systems into complex, event-driven asset classes they currently serve poorly.